Clinical trial · Interventional
Sperm Epigenome in Hodgkin Lymphoma
Multiparametric Detection and Preventive Approaches of Cancer Treatment-induced Epigenetic Instability in the Male Germline.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors. We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Disease Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Additional semen samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Epigenetic analysis in semen samples
- description
- 30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes
- interventionNames
- Other: Additional semen samples
Primary outcomes (2)
- measure
- Alterations in DNA methylation patterns in spermatozoa
- timeFrame
- Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
- description
- Sperm analysis : Methyl-C Capture Sequencing (MCC-seq)
- measure
- Alterations of histone 3 H3k4me3 retention sites in spermatozoa
- timeFrame
- Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Men aged 18 to 45 years * Diagnosed with Hodgkin lymphoma * Treatment-naïve to any cytotoxic therapy * Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD * Beneficiaries of the French social security system * Not opposed to participating in research Exclusion Criteria: * Patient receiving abdominal radiotherapy
References
Publications (0)
Data not yet available